There are many molecules being explored as potential biomarkers for cancer treatment, especially for cancer types with poor prognoses. The carcinoembryonic antigen family contains one such molecule that is a target of this exploration. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell surface glycoprotein that normally plays a role in intracellular signaling and cell adhesion. However, it is currently being investigated as a possible clinical biomarker due to its overexpression in various types of cancer. Specifically, CEACAM5 is being studied for its potential inhibition of cell differentiation and apoptosis, which can promote tumor growth, metastasis, and disruption of tissue architecture. Further investigation into CEACAM5, particularly into the differences in expression between normal and cancerous tissue, may provide a new target for treatment of these diseases.
Comments (0)